Reproductive history determines Erbb2 locus amplification, WNT signalling and tumour phenotype in a murine breast cancer model
Understanding the mechanisms underlying tumour heterogeneity is key to the development of treatments that can target specific tumour subtypes. We have previously targeted CRE recombinase-dependent conditional deletion of the tumour suppressor genes Brca1, Brca2, p53 (also known as Trp53) and/or Pten...
Saved in:
Main Authors: | Liliana D. Ordonez (Author), Lorenzo Melchor (Author), Kirsty R. Greenow (Author), Howard Kendrick (Author), Giusy Tornillo (Author), James Bradford (Author), Peter Giles (Author), Matthew J. Smalley (Author) |
---|---|
Format: | Book |
Published: |
The Company of Biologists,
2021-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Conditional in vivo deletion of LYN kinase has little effect on a BRCA1 loss-of-function-associated mammary tumour model
by: Giusy Tornillo, et al.
Published: (2024) -
Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab
by: Laure Thouvenin, et al.
Published: (2021) -
ERBB2‐amplified lobular breast carcinoma exhibits concomitant CDK12 co‐amplification associated with poor prognostic features
by: Miriam Forster‐Sack, et al.
Published: (2024) -
The MMTV-Wnt1 murine model produces two phenotypically distinct subtypes of mammary tumors with unique therapeutic responses to an EGFR inhibitor
by: Adam D. Pfefferle, et al.
Published: (2019) -
Development of ErbB2-Targeting Liposomes for Enhancing Drug Delivery to ErbB2-Positive Breast Cancer
by: Sho Ueno, et al.
Published: (2020)